(Q44290885)

1 December 2017

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies (English)

1 reference

1 December 2017

1 reference

1 reference

David Michelson

1

1 reference

1 December 2017

Lenard Adler

2

1 reference

1 December 2017

Thomas Spencer

3

1 reference

1 December 2017

Frederick W Reimherr

4

1 reference

1 December 2017

Scott A West

5

1 reference

1 December 2017

Albert J Allen

6

1 reference

1 December 2017

Douglas Kelsey

7

1 reference

1 December 2017

Joachim Wernicke

8

1 reference

1 December 2017

Anthony Dietrich

9

1 reference

1 December 2017

Denái Milton

10

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

1 December 2017

Biological Psychiatry

1 reference

1 December 2017

53

1 reference

1 December 2017

112-120

1 reference

1 December 2017

2

1 reference

Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Male testosterone linked to high social dominance but low physical aggression in early adolescence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

A rating scale for depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Long-term outcome of hyperactive children: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Attention deficit hyperactivity disorder adults: Comorbidities and adaptive impairments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Neuropsychological function in adults with attention-deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Bupropion treatment of attention-deficit hyperactivity disorder in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

The stimulants revisited.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901671-2

10.1016/S0006-3223(02)01671-2

7 January 2021

Identifiers

DOI

1 reference

1 December 2017

1 reference